Impax Laboratories Inc

Impax Laboratories — Investor Presentation (March 2008)

34 slides from Impax Laboratories's investor presentation, Mar 17, 2008

  1. Slide 1: Impax

    QD Impax

  2. Slide 2: Safe Harbor Statement

    Impax Laboratories, Inc. (IPXL.PK) "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expecta

  3. Slide 3: 10-K Filing Timeline 2004-2007 Audits

    10-K Filing Timeline 2004 - 2007 Audits 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q - -------------2005------------- ------------------2006------------------ --------------------2007---------------------2008------

  4. Slide 4: Overview

    Overview Technology-based specialty pharmaceutical company More than 140 R & D experts focused on formulating products that do not infringe existing patents Generic - Concentration on First-to-File, First-to-Market opportunities Brand - 505 (b)(2) NDA Candidates focused on CNS Significant commercial

  5. Slide 5: Technology and Drug Delivery Capabilities

    Technology and Drug Delivery Capabilities Patented techniques and know-how Patents issued: United States - 7; Foreign - 11 Pending applications: United States - 9; Foreign - 28 Substantial development experience - 114 products approved, pending or under development targeting over $30 billion in US p

  6. Slide 6: Technological Edge

    Technological Edge Technological Edge

  7. Slide 7: R&D Highlights for 2007

    R & D Highlights for 2007 Received 6 FDA approvals Final approvals for generic versions of: CORZIDE(r) 40/5mg, 80/5mg DITROPAN XL(r) 5,10mg XANAX(r) XR 0.5, 1, 2, 3mg LOPID(r) 600mg PERSANTINE(r) 25, 50, 75mg BACLOFEN 10, 20mg

  8. Slide 8: R&D Highlights for 2008

    R & D Highlights for 2008 Received 2 FDA approvals Final approvals for generic versions of: MYSOLINE(r) 50, 250mg PHENERGAN(r) 12.5, 25mg

  9. Slide 9: Commercial Highlights for 2007

    Commercial Highlights for 2007 Launched 5 new products Generic versions of: COLESTID(r) Tablets 1g URECHOLINE(r) 5, 10, 25, 50mg DITROPAN XL(r) 5, 10mg CORZIDE(r) 40/5mg, 80/5mg PERSANTINE(r) 25, 50, 75mg

  10. Slide 10: Commercial Highlights for 2008

    Commercial Highlights for 2008 Launched 2 new products Generic versions of: MYSOLINE(r) 50mg, 250mg PHENERGAN(r) 12.5mg, 25mg

  11. Slide 11: Research and Development Strategy

    Research and Development Strategy

  12. Slide 12: Formulation Expertise

    Formulation Expertise Applied Technology Candidates Generic Products First-to-File First-to-Market Limited Competition Products Branded Products CNS Products

  13. Slide 13: Technology

    Technology State-of-the art formulation techniques Diverse oral-solid formulation capabilities Targeting products with limited competition Controlled release projects where our substantial experience allows us to formulate around existing patents Specialty formulation projects where we focus on diff

  14. Slide 14: Outsourced Product Development

    Outsourced Product Development Complements (and leverages) internal programs Directed programs 4 offshore companies 13 projects outsourced 6 already submitted and 2 approved

  15. Slide 15: Substantial and Growing Manufacturing Capacity

    Substantial and Growing Manufacturing Capacity Hayward operations 1.2 billion unit annual capacity Taiwan plant underway Initial phase - 50% increase Fully approved and operational early 2010

  16. Slide 16: Taiwan Construction

    Taiwan Construction $25 million capital budget All production for export to the US Will be one of only a few FDA approved dosage form plants in Asia

  17. Slide 17: Generic Target Market

    Generic Target Market Immediate Release Immediate Release Controlled Release Controlled Release Total Total # Market # Market # Market Pending at FDA 9 $636 13 $10,048 22 $10,684 Under Development 15 $3,635 34 $14,101 49 $17,736 Total 24 $4,271 47 $24,149 71 $28,420 Market - US Market size in millio

  18. Slide 18: Jot

    Jot pee Develop- meni, $17,736 | 18

  19. Slide 19: Paragraph-IV Generic Products Filings

    Paragraph-IV Generic Products 26 Filings Impax Project Generic of* Est. Filing Order** Initial Filing Omeprazole 10,20,40mg DR PRILOSEC(r) (AZN) 5th of 10 total 4Q99 Bupropion 100,150mg ER WELLBUTRIN(r) SR (GSK) 3rd of 5 total 2Q00 Bupropion 150mg ER ZYBAN(r) (GSK) 2nd of 4 total 2Q00 Fenofibrate 67

  20. Slide 20: Paragraph-IV Generic Products

    Paragraph-IV Generic Products Impax Project Generic of* Est. Filing Order** Initial Filing Carbidopa/Levodopa ER SINEMET(r) CR (BMS) 2nd of 4 total 4Q02 Carprofen 25,75 &100mg (Vet) RIMADYL(r) (Pfizer) 1st of 2 total 4Q02 Bupropion 200mg ER WELLBUTRIN(r) SR (GSK) 1st of 2 total 1Q03 Oxybutynin 5,10,

  21. Slide 21: Paragraph-IV Litigation Status

    Paragraph-IV Litigation Status Project Litigation Status Omeprazole 10, 20 & 40mg DR May 2007 trial court decision that Impax product infringes; patent not invalid. On appeal to the CAFC. Fexofenadine & PSE ER No trial date scheduled. Venlafaxine 37.5, 75, 150mg ER Trial scheduled April 2008. Divalp

  22. Slide 22: Commercial Strategy

    Commercial Strategy Competitive advantages - How we are different Broad-based Approach Multiple commercial outlets in uniquely diverse categories Customer focus Product selection - provide customers with generics that are somewhat unique Equally responsive to near-term customer needs and long-term c

  23. Slide 23: Commercial Strategy: Primary Commercial Outlets

    Commercial Strategy Primary Commercial Outlets: Global Pharmaceuticals Division (Generic) Highly experienced generic field sales organization currently supplying ALL major U.S. generic purchasers Fully integrated internal customer service organization; including electronic commerce (EDI, electronic

  24. Slide 24: Commercial Strategy: Strategic Alliances

    Commercial Strategy - -Strategic Alliances- Supplemental Commercial Outlets: TEVA - 12 products, 9 launched (only 22% of all 41 marketed products) DAVA - Oxycodone (OXYCONTIN(r)) 2nd Marketing period concluded Opportunistic Only if and when valuable

  25. Slide 25: Brand Projects

    Mice 2008 Brand Projects CD IMPAX

  26. Slide 26: Brand Projects

    Brand Projects Improved versions of marketed products Same R & D platform Clinical development Focused on CNS Smaller, more concentrated addressable market

  27. Slide 27: VADOVA

    VADOVA(tm) Value proposition Potentially higher patient compliance through reduced pill burden Received non-approvable letter January 2008 Nomenclature issues with the established name Evaluating options

  28. Slide 28: Branded Products Pipeline

    Branded Products Pipeline IPX056 Under clinical evaluation Clinical study targeted completion 2008 Data analysis and NDA submission target 2009 IPX066 and IPX111 clinical evaluations in 2008/2009

  29. Slide 29: Brand Marketing and Sales

    Brand Marketing and Sales 66 Reps calling on targeted neurologists with CARBATROL(r) (Shire) $39 million funding through 6/2009 Relationships that will facilitate marketing future internal brand products with Impax

  30. Slide 30: Significant Filing Milestones

    Significant Filing Milestones *Includes amendments to two previously filed applications-not included in 2005 applications filed Filing Goal 2008: 8-10 with focus on controlled-release products 2000/ 2002 2003 2004 2005 2006 2007 2008 (YTD) Applications Filed 24 8 6 10 6 7 PPG IV filings 14 4 1 3* 1

  31. Slide 31: Applications Filed and Approved or Pending Approval

    Applications Filed and Approved or Pending Approved2 Approved2 Approved2 Approved2 Approved2 Approved2 Filed 2004 2005 2006 2007 2008 Pending Applications Filed1 2003 6 1 3 1 1 Applications Filed1 2004 5 1 4 Note3 Applications Filed1 2005 9 1 3 2 3 Applications Filed1 2006 6 2 4 Applications Filed1

  32. Slide 32: Financials

    Financials Dec-06 = Mar.07 = Ju. 07 Sep-07 —_Dee.07(¢) (in thousands and unaudited) Cash and Investments $29,453 $47,071 $62,451 $142,152 $138,533 Long-Term Debt $89,600 $89,161 $86,527 $ 86,090 $ 82,760 Capital Expenditures $20,793 $6,269 $11,247 $15,686 $20,686 (Q2Months) Months) (Months) (9 Month

  33. Slide 33: Strong Management Team

    Strong Management Team Larry Hsu, Ph.D., President & CEO 30 years of experience, Abbott Laboratories, co-founded Impax David Doll, EVP Commercial Operations 20+ years of experience, Merck and Teva Arthur A. Koch, Jr., SVP, CFO 30 years of experience, Strategic Diagnostics, IBAH Inc., KPMG LLC Charle

  34. Slide 34: Highlights

    Highlights Broad-based drug delivery technology Strong product portfolio "Renewable" Strong management team Brand products offer long-term growth driver

Impax Laboratories — Investor Presentation (March 2008) on 6ix